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The soluble transferrin receptor as a marker of iron
homeostasis in normal subjects and in HFE-related
hemochromatosis
Iron delivery to cells is mediated by theinteraction of plasma transferrin withcell surface transferrin receptors.
Virtually all cells have transferrin receptors
on their surface although, in the normal
adult, about 80% of them are in the ery-
throid marrow.1 Circulating soluble trans-
ferrin receptors (sTfR) found in human
plasma provide an estimate of the ery-
throid compartment mass.2 The concentra-
tion of sTfR is significantly increased in the
presence of iron deficient anemia or
enhanced erythropoiesis,3 but some contro-
versy remains about its significance as a
marker of iron status in overload condi-
tions.4 Hereditary hemochromatosis (HH),
a common genetic disorder of iron over-
load, constitutes a good model to address
this question. HH is characterized by inap-
propriately increased iron absorption with
progressive accumulation of iron in tissues
and eventual organ damage. The large
majority of HH patients are homozygous
for a mutation in the HFE gene that causes
a change in the HFE protein,  from cysteine
to tyrosine at position 282 (C282Y), impair-
ing the normal association of HFE with β2-
microglobulin, therefore reducing its cell
surface expression.5 Phenotypically, HH is
recognized by abnormally high levels of
transferrin saturation (TfSat) and serum fer-
ritin, reflecting, respectively, increased iron
absorption and iron accumulation in tis-
sues. Subjects with the hemochromatosis
phenotype, homozygous for the C282Y
HFE mutation, exhibit a higher erythrocyte
mass, as measured by the hemoglobin con-
centration,6,7 suggesting an increased iron
uptake and hemoglobin synthesis by ery-
throid cells.6 Despite the strong association
of the mutated HFE protein with iron over-
load, its role in the regulation of iron bal-
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Background and Objectives. The soluble transferrin receptor (sTfR) is a clinical marker of erythro-
poietic activity, also used in the diagnosis of iron deficiency. In the present paper we explore the
meaning of this parameter in normal physiological conditions of iron homeostasis and in the set-
ting of iron overload due to hereditary hemochromatosis (HH).
Design and Methods. Reference values for sTfR were established in a population of 42 appar-
ently healthy subjects, analyzed in relation to other hematologic parameters, namely, hemoglo-
bin (Hb), mean corpuscular volume (MCV), transferrin saturation (TfSat) and serum ferritin. The
same analysis was done in a group of 45 patients with HH who were homozygous for the C282Y
mutation of HFE and had a wide range of TfSat values. In addition, individual serial profiles were
analyzed in three patients.
Results.  In normal subjects circulating sTfR correlated significantly with the TfSat level, reflect-
ing the systemic effect of iron availability on the erythropoietic activity in a normal physiological
steady state. A TfSat of 25% appeared as a threshold value, below which there was a progres-
sive increase in sTfR; this increase in sTfR occurred concomitantly with a decrease in Hb, MCV
and serum ferritin. In HH patients the up-regulation of sTfR started at TfSat values as high as
50%. 
Interpretation and Conclusions. The fact that sTfR up-regulation started at higher TfSat values
in HH patients suggests that the recognition of systemic iron available for erythropoiesis is
altered in this condition. Based on these results, a new hypothesis is advanced, proposing that
the HFE protein in involved as a sensor of systemic iron availability, via the soluble transferrin
receptor.
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ance is not understood. The lack of hepcidin up-regu-
lation in HH,8 supported by results in animal models,9,10
suggests that HFE may play an important part in the
regulation of hepcidin expression. However, the func-
tional relationship between HFE and hepcidin is still
obscure. So far, the only confirmed link between the
HFE-β2 microglobulin complex and other proteins of
iron homeostasis is the observation that HFE binds
with high affinity to the transferrin receptor.11-13
Previous studies addressing the question of sTfR in
HH patients have provided conflicting results.
Independent studies by Huebers et al.14 and Baynes et
al.,15 found no differences in sTfR between HH patients
and controls. In contrast, Ledue and Craig reported
that the serum concentration of sTfR is 30% lower in
HH patients.16 One explanation for the discrepancies
found could be the fact that the different studies
include highly heterogeneous groups of patients, clini-
cally characterized before the discovery of the HFE
gene. Another problem could be the fact that not all
patients were analyzed at the same stage of phleboto-
my treatment. A direct and significant relationship
between the number of phlebotomies and sTfR con-
centration was described in HH.16 Accordingly, an
inverse correlation between the sTfR and serum fer-
ritin or TfSat was observed in African iron overload.17
The objective of the present study was to characterize
the relationship between the serum concentration of
sTfR and other hematologic and biochemical parame-
ters of iron homeostasis in HH patients homozygous
for the C282Y mutation of HFE, and compare these
with appropriate reference values for sTfR in relation
to iron parameters in a local normal healthy popula-
tion.
Design and Methods
Subjects and study design
HH patients
Forty-five HH patients (29 males and 16 females; age
range=24-77 years) were included in this study. All
patients were diagnosed and are regularly followed-up
at the Haemochromatosis Outpatient Clinic of Santo
António General Hospital, Porto, where all the clinical
information is recorded. Only patients genetically
characterized as homozygous for the C282Y mutation
of HFE were included. Clinical and genetic data from
these patients have been published previously.18,19,20 For
the purpose of the present study, measurement of
sTfR was included as a routine procedure in the regu-
lar analytical evaluation of patients. During the study
period, patients were at different stages of their treat-
ment course. Fifteen patients were under intensive
phlebotomy treatment: 10 of them at the beginning
and 3 at the end of treatment, i.e., near iron depletion.
The remaining 30 were receiving maintenance thera-
py. The inclusion of patients at different stages of iron
load was important in order to allow an analysis of
sTfR values in relation to a wide range of TfSat values.
In addition, for the purpose of defining some individ-
ual serial profiles, we retrospectively analyzed the
sTfR in frozen stored samples collected at regular
intervals during the treatment period in three patients:
two patients (one male and one female aged, respec-
tively, 45 and 60 years) who were followed-up from
diagnosis until one year after the end of intensive
treatment; and one patient who presented with ane-
mia and was followed-up regularly during the first six
months of intensive phlebotomy treatment. All clini-
cal material was collected and stored with the
informed consent of the patients.
Control population
The sTfR was measured in 43 apparently healthy
subjects (14 males and 29 females; age range=21-53
years) used as a reference population for the purpose of
this study. Twelve of these subjects were randomly
recruited from among the population of regular blood
donors of Santo António General Hospital, Porto and
31 subjects were healthy family members of HH
patients, studied as part of a routine screening program
for hemochromatosis at the Predictive and Preventive
Genetic Centre, Porto. Homozygosity for the C282Y
allele was excluded in all control subjects. The labora-
tory studies for all subjects included a complete blood
cell count and biochemical parameters of iron status.
Informed consent for the study was obtained from all
recruited subjects.
Laboratory parameters
Blood counts and iron parameters were determined
by standard automatic methods routinely used at the
Haematology Laboratory and Clinical Chemistry
Laboratory of Santo António General Hospital, Porto.
The sTfR was measured by an automatic immunotur-
bidimetric assay COBAS INTEGRA 700 system using a
commercially available kit (Tina-quant→Soluble
Transferrin Receptor, Roche). In 13 random control
cases, the sTfR test was performed in duplicate in
freshly collected samples and samples that had been
frozen at -20°C; no significant alterations were
observed in results obtained after freezing (data not
shown).
Statistical analysis
Correlations between variables were investigated by
simple regression analysis. For the purpose of describ-
ing variations of the several parameters as a function of
transferrin saturation levels, piecewise linear regres-
sions were run for several breakpoints in controls and
patients separately. The breakpoints chosen and
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shown in figures were selected by the best-fitted mod-
els within each group. Group means were compared
by Student’s t-test, or ANOVA when multiple groups
were compared. Distribution fitting was tested by the
Kolmogorov-Smirnov method. For the purpose of
analysis, logarithmic transformation was applied to the
values of serum ferritin, since these have a logarithmic
distribution. However, the non-transformed values are
presented in Table 1. All p values are two-sided and
0.05 was taken as the level of statistical significance.
Data were analyzed by StatGraphics software
(Statgraphics Statistical Graphics System, version 4.0).
Results
Control population (Figure 1)
The control population consisted of 14 males and 29
females with ages ranging from 21 to 53 years. The
average hemoglobin values (in g/dL) were 14.9±1.3
(range=12.3-16.6) in males and 13.1±0.8 (range=11.9-
15,7) in females. TfSat values (in %) varied from 20 to
46 (mean=32±9) in males and from 10 to 48
(mean=26±10) in females. The sTfR values (in mg/L)
varied from 1.84 to 5.74 with no significant differences
between males and females (respectively 2.8±0.6 and
3.1±0.9). These values were normally distributed (esti-
mated overall statistic DN=0.15; p=0.274). No signifi-
cant differences were found with age. In order to ana-
lyze the relationship between the sTfR values and the
other hematologic parameters, linear regression analy-
ses were run between the sTfR and haemoglobin (Hb),
mean corpuscular volume (MCV), transferrin satura-
tion (TfSat) and the log of serum ferritin. The results
show that sTfR is strongly correlated with all except
the Hb values (see Table 1). As expected, the most sig-
nificant correlation was found for serum ferritin. In
addition, a similarly strong correlation was found for
TfSat. This finding led us to test all other parameters
in relation to the TfSat values. Figure 1 illustrates the
distribution of the hematologic parameters in relation
to the TfSat values in the control population.
Piecewise linear regressions were run for several
breakpoints of transferrin saturation. Three break-
points (20%, 25% and 30%) were chosen a priori by
inspection of the scatter plot for the whole range of
TfSat, and linear regressions were run for values under
or above the respective breakpoints. The best-fitted
Table 1. Correlation between the soluble transferrin receptor and
other hematologic parameters in the control population. The R2, r
and p values are shown for each regression.
Soluble Transferrin Receptor
Hgb MCV TfSat Ferritin (Log)
R squared (R2) 0.08 0.17 0.22 0.28
Correlation coefficient (r) -0.28 -0.41 -0.47 -0.53
Significance level (p) 0.068 0.006 0.0016 0.0004
Figure  1. Regression analyses between the transferrin saturation (TfSat) values and the values of hemoglobin (Hb), mean corpuscular
volume (MCV), serum ferritin and soluble transferrin receptor (sTfR) in normal controls. Significant correlations are indicated by a full
regression line. Dotted regression lines represent non-significant correlations. 
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models were obtained for the breakpoint of 25%.  For
TfSat values lower than 25%, significant positive cor-
relations were found between TfSat and the values of
Hb (R2=0.30; r=0.55; p=0.033), MCV (R2=0.41; r=0.64;
p=0.010) and serum ferritin (R2=0.41; r=0.64; p=0.010),
whereas no significant correlations were found for
TfSat values greater or equal than 25%. The sTfR, in
contrast, increased significantly with decreasing TfSat
values below 25% (R2=0.35; r=-0.59; p=0.019), but
remained at stable low levels for TfSat values from 25
to 50%. No TfSat values higher than 50% were
observed in the control population.
HH patients (Figure 2)
In the light of the results described above in the
control population, hematologic parameters were
analyzed in HH patients also in relation to the TfSat
values (Figure 2). For the whole range of TfSat values,
highly significant positive correlations were found
for MCV (R2=0.27; r=0.52; p=0.0003) and serum fer-
ritin (R2=0.59; r=0.77; p<0.0001). In the case of Hb
and sTfR, piecewise linear regressions were also run
for several breakpoints of transferrin saturation.
Three breakpoints (25%, 40% and 50%) were cho-
sen a priori based on the model obtained in controls
and by inspection of the scatter plot for the whole
range of TfSat. The best-fitted model was obtained
for the breakpoint of 50%. Hb values decreased sig-
nificantly with decreasing values of TfSat, when
these were lower than 50% (R2=0.35; r=0.59,
p=0.006), while a negative correlation was found for
TfSat greater or equal than 50% (R2=0.18; r=-0.43;
p=0.043). This resulted in significantly lower Hb val-
ues in the group of patients with TfSat>70% than in
the group of patients with TfSat between 50 and
70% (respectively 13.7±1.5 and 15.3±0.4; p=0.024).
The sTfR values were also dependent of TfSat. They
increased significantly with decreasing TfSat values
below 50% (R2=0.56; r=-0.75; p=0.0002), but
remained at stable low levels for TfSat values
between 50 and 100%. 
Since the regression analyses illustrated in Figure 2
for the whole range of TfSat values were predicted
from a group of independent subjects, it was impor-
tant to confirm whether the predictions could be
applied in individual cases. For this purpose, regres-
sion analyses between the TfSat and sTfR were run
for serially determined values in two individual
patients during the course of phlebotomy treatment.
As illustrated in Figure 3, for TfSat values under 50%,
highly significant correlations were confirmed in
both the male (R2=0.90; r=-0.95; p=0.0131) and the
female (R2=0.87; r=-0.93; p=0.00003) patients, fitting
the regression model predicted for the whole group
Figure 2. Regression analyses between the transferrin saturation (TfSat) values and the values of hemoglobin (Hb), mean corpuscular
volume (MCV), serum ferritin and soluble transferrin receptor (sTfR) in C282Y homozygous HH patients. Significant correlations are indi-
cated by a full regression line. Dotted regression lines represent non-significant correlations. 
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of patients and not the regression line predicted for
the normal subjects (red line in Figure 3). The sTfR
values were further analyzed serially for a follow-up
period of six months during intensive phlebotomy
treatment in one patient who presented with ane-
mia. The results are shown in Figure 4 in comparison
with the serial values of Hb and TfSat. A progressive
increase in Hb values was observed in the course of
the first 14 weekly phlebotomies, together with an
increase in the sTfR and decrease in TfSat.
Comparisons between HH patients and
controls (Table 2)
For the purpose of comparing the hematologic para-
meters in patients and controls, subjects were divided
into groups according to the range of TfSat values (10-
25%; 25-50%; ≥50%). As shown in Table 2, for TfSat
values ranging from 10% to 50%, HH patients did not
differ significantly from controls, although the mean
value of sTfR was higher in HH patients than in  con-
trols within the group with TfS at 10-25%. For TfSat
values greater or equal than 50%, HH patients had sig-
nificantly higher values of MCV and serum ferritin, and
significantly lower values of sTfR (see Table 2).
Discussion
In clinical practice, measurement of the sTfR is used
for the diagnosis of iron deficiency as an additional
parameter to other conventional laboratory tests of
iron status, with the advantage that it is not influenced
by acute phase responses.1 Furthermore, it is a non-
invasive and sensitive means of evaluating bone mar-
row iron stores2 providing a good alternative to bone
marrow aspirate examination, an invasive procedure
that can be inadequate for interpretation in 35% of
cases.1 Besides its clinical value in iron deficiency, the
sTfR level is also an indicator of erythropoietic activity.
Low values of sTfR are observed in hypoplastic ery-
thropoiesis,14 and increased values are seen in erythroid
hyperplasia, independently of iron stores.14,21 The find-
ing of increased values of sTfR in secondary iron over-
load associated with erythroid hyperplasia led, some
time ago, Cazzola and co-workers to suggest that, in
these situations, the increased sTfR, through its inter-
action with HFE, could be one potential determinant of
the secondary iron overload,21 suggesting a role for
sTfR in iron absorption. This hypothesis has never
been tested. The present study of sTfR in healthy sub-
jects and in HH patients provided an opportunity to
gain insight into the receptor’s biological significance
outside the setting of iron deficiency or ineffective ery-
thropoiesis. The results in normal subjects (Figure 1)
show that the levels of circulating transferrin receptors
are significantly correlated with the transferrin satura-
tion level, reflecting the systemic effect of iron avail-
Figure 3. Correlation between the individual soluble transferrin
receptor (sTfR) and transferrin saturation (TfSat) values in two
C282Y homozygous HH patients (sex and age indicated). The
regression analyses were run with values obtained at different
times of treatment. The regression lines obtained in each patient
are represented as blue lines and compared with the regression
line obtained in the group of normal controls (red lines).
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Table 2. Comparison of hematologic values between HH patients and controls, in groups defined according to different levels of trans-
ferrin saturation.
Controls HH patients*
Groups TfSat [10-25%] TfSat [25-50%] TfSat [10-25%] TfSat [25-50%] TfSat≥50%
(n=15) (n=28) (n=7) (n=12) (n=25)
Hgb (g/dL) 13.2±1.0 (12.3-15.9) 14.0±1.4 (11.9-16.6) 11.6±2.5 (8.6-14.6) 14.1±1.7 (11.5-17.0) 14.2±1.5 (11.0-16.1)
MCV (fL) 87±6 (77-97) 91±4 (82-98) 89±5 (80-95) 93±6 (85-105) 96±6 (83-105)°
Ferritin (ng/mL) 46±51 (2-187) 115±204 (7-880) 17±16 (2-47) 78±158 (2-570) 1328±2014 (6-6517)*
sTfR (mg/mL) 3.45±1.06 (2.26-5.74) 2.73±0.54 (1.84-4.08) 4.12±1.32 (2.43-6.13) 2.87±0.60 (1.76-4.27) 2.42±0.55 (1.59-3.92)@
*Only one patient was excluded for this table for having TfSat <10%; °significantly different from controls (p<0.0001); *significantly different from all other groups
(p<0,03); @significantly different from all other groups (p<0.004).
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ability on erythropoietic activity in a normal physio-
logical steady state. For practical purposes, a normal
level of circulating sTfR should be predicted in the con-
text of the individual TfSat level (Table 2 and Figure 1).
A TfSat of 25% appeared to be the threshold value
below which there was a progressive increase in sTfR,
in parallel with decreases in Hb, MCV and serum fer-
ritin in normal controls. This reflects a critical value of
TfSat that could determine the up-regulation of sTfR
before the development of iron-deficient anemia. For
TfSat values above 25%, the sTfR is stable in a normal
range, as are Hb, MCV and serum ferritin levels. This
homeostatic equilibrium seems, in turn, to control the
TfSat itself, since this is also stabilized at values
between 25% and 50% without further increase. This
control is supposed to be mediated by the regulation of
iron absorption.
The idea that the erythropoietic activity, as clinically
expressed by the levels of sTfR, is a determinant in the
regulation of iron absorption led us to test the hypoth-
esis that this physiological mechanism could somehow
be abnormal in HH. In this context, we measured the
sTfR in HH patients, all homozygous for the C282Y
mutation, who had a large range of transferrin satura-
tion values. The results show that the critical value for
the up-regulation of sTfR in these patients is not 25%
but may be as high as 50%. The increase in sTfR for
higher TfSat values suggests that the sensing of iron
available for erythropoiesis is somehow altered, behav-
ing in iron-loaded conditions as it would in iron deple-
tion. The consequence of this may be an increase in
iron absorption that, in turn, would contribute to the
increase of TfSat and perpetuation of this cycle.
Probably this is not the case in other conditions of mild
to moderate non-HFE hemochromatosis, in which
TfSat values are not increased as in HFE-linked HH.
Taking into account the fact that the appearance of
marrow erythroid cells, rates of erythroid cell produc-
tion and destruction, and hemoglobin are normal in
HH,22,23 it can be assumed that inappropriately high lev-
els of sTfR are not due to increased erythrocyte
turnover, with or without ineffective erythropoiesis.
The observation that the threshold for the up- or
down-regulation of sTfR is altered in HH is further sup-
ported by the data on the follow-up of two patients
who show individual correlations fitting well with the
predicted model (Figure 3). The model is compatible
with the prediction that there is increased iron uptake
and hemoglobin synthesis by erythroid cells in HH, as
described before by Barton and co-workers.6 For TfSat
values above 50% the sTfR is stabilized or down-regu-
lated, thus limiting the iron uptake and further increase
in hemoglobin synthesis. In these circumstances, the
excessive iron available does not lead to a correspon-
ding increase in hemoglobin (on the contrary, it
decreases) but, instead, leads to iron accumulation in
tissues as reflected by the increasing serum ferritin.
This explains the finding of lower Hb values in patients
with the highest TfSat (>70%), a situation that can be
corrected by treatment, as illustrated by the follow-up
of one heavily iron-overloaded patient who presented
with anemia, and whose Hb increased in the course of
intensive phlebotomy treatment, with a decrease in
TfSat and an increase in sTfR (Figure 4). 
The hypothesis of altered iron sensing by a mutant
HFE protein is compatible with the specificity of cer-
tain organs or cells that are targets for iron overload in
HH, and the lack of iron in other cell types such as
macrophages and intestinal epithelial cells. According
to the molecular model proposed by Townsend and
Drakesmith,24,25 the HFE protein has two mutually
exclusive activities in cells: inhibition of iron uptake
(through binding to the transferrin receptor, in compe-
tition with transferrin) or inhibition of iron release.
According to their model, the balance between TfSat
and sTfR concentrations determines which of these
functions predominates. In this way, the intestinal
| 36 | haematologica/the hematology journal | 2005; 90(1)
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Figure 4. Serial values of hemoglobin, soluble transferrin recep-
tor and transferrin saturation during a 6-month period of inten-
sive phlebotomy treatment in one HH patient who presented with
anemia.
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crypt cells and reticuloendothelial system may inter-
pret the body’s iron requirements and regulate iron
absorption and distribution, a function that fails in HH.
From a systemic perspective, it is plausible that the two
functions are performed simultaneously in different
cell types with the common purpose of satisfying cel-
lular iron needs. In conditions in which iron is required,
there is both an increase in iron absorption and release
from reticuloendothelial cells, and an increase in iron
uptake by dividing cells which express transferrin
receptors. The finding of increased sTfR could be a
reflection of the cells’ proliferative state (which is
mainly influenced by the erythroid mass, but could
possibly receive contributions from other cell types
such as lymphocytes). They could also contribute to
the regulation of iron uptake. We speculate that this
could happen through competitive binding of the
transferrin receptor, either on the cell surface or in the
circulation, to HFE. In conclusion, the present results
support the notion that a key role of HFE in iron home-
ostasis is the sensing or recognition of systemic iron
availability. Both the transferrin saturation (reflecting
systemic iron availability) and the soluble transferrin
receptor (reflecting erythroid activity) are good candi-
dates as signals in this model. 
This does not exclude a role for HFE in signaling
other effector molecules. Its postulated involvement
also in the regulation of hepcidin activity may justify
the importance of hepcidin as a modifier of expression
of hemochromatosis, as elegantly reviewed by
Pietrangelo in 2004.26
It is possible that the HFE protein, as a MHC class I
protein present in a great diversity of cell types, has
even wider regulatory functions, as reviewed by
Cardoso and De Sousa.27
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